Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that its Chief Medical Officer, Amir Inamdar, will take part in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The conference is scheduled for June 15-16, 2026, and the fireside chat will be available on demand starting June 15 at 7:00 a.m. EDT.
This announcement underscores Helus Pharma's ongoing efforts to engage with the investment community and showcase its pipeline of proprietary NSAs. The company's lead candidate, HLP003, is currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. Helus Pharma also maintains an extensive research portfolio of investigational NSAs aimed at addressing unmet needs in mental health.
The participation of Dr. Inamdar, who oversees the company's clinical strategy, provides an opportunity for investors and analysts to gain insights into the company's clinical programs and future directions. The H.C. Wainwright conference is a notable event in the biotech sector, attracting a range of industry participants. For more details, the full press release can be accessed at https://ibn.fm/KsnJW.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, focuses on developing synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to improve the treatment landscape for depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma seeks to provide durable improvements in mental health through its NSA platform.
The company operates in Canada, the United States, the United Kingdom, and Ireland. More information about Helus Pharma and its pipeline is available at www.helus.com. The latest news and updates regarding HELP can be found in the company's newsroom at https://ibn.fm/HELP.
